Get your free ETF data sample from our comprehensive offerings. Start your free trial

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Global ETF Survey 2026
ETF IssuersiShares2B78
2B78

iShares Healthcare Innovation UCITS ETF

The 2B78 Exchange Traded Fund (ETF) is provided by iShares. It is built to track an index: STOXX Global Breakthrough Healthcare Index. The 2B78 ETF provides physical exposure, so by buying it you actually own parts of all the 201 underlying holdings. The dividend policy is capitalization.

Advertisement

Advertisement

€8.56
+€0.082 (+0.97%) 3 days ago
6:00 AM 07/28/26 Open
1D price range
€8.47€8.60
52W price range
€7.59€9.89
YTD Perf.
+8.02%
YTD Flows
Annualized volatility
Fund AuM
€1.04B
Share class AuM
€1.04B
TTM Yield
-
Tracking Error
Tracking Difference
ISIN
IE00BYZK4776
TER
0.4%
Inception date
9/8/2016
Issuer
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 31, 2025 - Jul 29, 2026
-5%0%5%10%JANMARMAYJUL
Flows
Join for free to unlock
Data as of 06/30/26
Healthcare
99.59%
Unavailable
0.21%
Other
0.20%
Latest 2B78 news

No content available for this fund

FAQ about 2B78

2B78 is a Passive ETF. This ETF provides exposure to Other Equities.
2B78 tracks the STOXX Global Breakthrough Healthcare Index - USD, through a optimized sampling replication method.
2B78 carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.
2B78 was introduced to the market on September 8, 2016. It trades on Portugal, among other exchanges
iShares Healthcare Innovation UCITS ETF, 2B78, is provided by iShares. Learn more about iShares here.
2B78 oversees €1.04B in assets as of July 29, 2026.
2B78 follows a capitalizing, meaning it reinvests income within the fund.
As of June 30, 2026, 2B78 has significant geographic allocations in USA, Switzerland and Japan.
As of June 30, 2026, 2B78 focuses largely on Healthcare.
As of June 30, 2026, 2B78 holds 201 positions in its portfolio, with 22.98% of assets concentrated in its top 15 holdings.
As of June 30, 2026, 2B78 top three holdings include Moderna, Inc., Roivant Sciences Ltd. and Natera, Inc..
The base currency of 2B78 is USD.
Data as of 06/30/26
Moderna, Inc.
1.99%
Roivant Sciences Ltd.
1.66%
Natera, Inc.
1.66%
Guardant Health, Inc.
1.57%
AbbVie, Inc.
1.52%
Genmab A/S
1.50%
Illumina, Inc.
1.49%
Lonza Group AG
1.48%
Biogen, Inc.
1.47%
Merck & Co., Inc.
1.46%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight